{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041662","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.055525+00:00","generated_at":"2026-06-08T00:49:02.973010+00:00","sec_items":["5.02","5.07"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Director Edward Chan resigns from Interpace board; annual meeting results filed","bullets":["Edward Chan resigned as Class II director effective Nov 15, 2023, not due to any disagreement.","Annual meeting held Nov 14, 2023; stockholders elected Thomas W. Burnell and Joseph Keegan as Class III directors.","Non-binding advisory vote on executive compensation approved with 9,177,922 for, 73,760 against.","Ratification of EisnerAmper LLP as auditor for FY 2023 approved with 10,907,312 for, 42,734 against.","Advisory vote on frequency of compensation votes: 9,089,392 voted for every three years (the board's recommendation)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041662","json":"https://secwatch.observer/filing/0001493152-23-041662.json","markdown":"https://secwatch.observer/filing/0001493152-23-041662.md","text":"https://secwatch.observer/filing/0001493152-23-041662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223041662/0001493152-23-041662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223041662/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:49:02.973010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d739e1ddea","claim":"Edward Chan resigned as Director at INTERPACE BIOSCIENCES, INC..","evidence_excerpt":"On November 15, 2023, Edward Chan, a Class II director designated by 1315 Capital II, L.P. to the board of directors (the “ Board ”) of Interpace Biosciences, Inc. (the “ Company ”), provided notice to the Company of his resignation from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223041662/0001493152-23-041662-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"34e444ba74e6eed6d5f280e5342269402c7788a7","claim":"INTERPACE BIOSCIENCES, INC. shareholders approved A non-binding advisory vote on a resolution approving the compensation of our named executive officers. at the 2023-11-14 meeting.","evidence_excerpt":"A non-binding advisory vote on a resolution approving the compensation of our named executive officers. For Against Abstain Broker Non-Vote 9,177,922 73,760 85,887 1,615,870","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223041662/0001493152-23-041662-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-14"}],"fact_type":"shareholder_vote"},{"claim_id":"4a8cc5706095f044d75fbc366b2e4bbd93978a4b","claim":"INTERPACE BIOSCIENCES, INC. shareholders approved A non-binding advisory vote on the frequency of executive compensation advisory votes. at the 2023-11-14 meeting.","evidence_excerpt":"A non-binding advisory vote on the frequency of executive compensation advisory votes. Every One Year Every Two Years Every Three Years Abstain Broker Non-Vote 202,362 10,069 9,089,392 35,746 1,615,870","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223041662/0001493152-23-041662-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-14"}],"fact_type":"shareholder_vote"},{"claim_id":"5669d32fed8904112d4ac39d552b8ea44db60029","claim":"INTERPACE BIOSCIENCES, INC. shareholders approved Election of two Class III directors to serve until the 2026 annual meeting or until each such director's successor is duly elected and qualified. at the 2023-11-14 meeting.","evidence_excerpt":"Election of two Class III directors to serve until the 2026 annual meeting or until each such director's successor is duly elected and qualified. Name For Withhold Broker Non-Vote Thomas W. Burnell 9,294,768 42,801 1,615,870 Joseph Keegan, Ph.D. 9,191,329 146,240 1,615,870","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223041662/0001493152-23-041662-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-14"}],"fact_type":"shareholder_vote"},{"claim_id":"ae91c73c000c1836015e4f965c028f8c0380c29c","claim":"INTERPACE BIOSCIENCES, INC. shareholders approved Ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-11-14 meeting.","evidence_excerpt":"Ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain Broker Non-Vote 10,907,312 42,734 3,393 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315223041662/0001493152-23-041662-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}